上市公司資料
 
杭州泰格醫藥科技股份有限公司 股票代號:  03347
HANGZHOU TIGERMED CONSULTING CO., LTD. 集團網址: http://www.tigermedgrp.com
損益表
  2023/12
RMB(K$)
變動 2022/12
RMB(K$)
2021/12
RMB(K$)
營業額7,384,0394.214%7,085,4715,213,538
經營溢利/(虧損)2,385,008-6.659%2,555,1493,675,154
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)105,183164.525%39,76314,348
稅前溢利/(虧損)2,490,191-4.036%2,594,9123,689,502
稅項(338,606)--(313,652)(292,864)
少數股東權益(125,078)--(265,174)(517,539)
股東應佔溢利/(虧損)2,026,5070.517%2,016,0862,879,099
 
淨利息收入/(支出)110,927-23.630%145,249234,139
折舊與攤銷339,02419.021%284,844196,762
董事酬金8,92913.442%7,8713,487
 
每股盈利/(虧損)(仙)234.0000.429%233.000332.000
每股派息(仙)56.8003.273%55.00050.000
 
派息比率(%)24.274%--23.605%15.060%
每股帳面資產淨值($)24.1507.340%22.49920.844
主要財務比率
  2023/12
RMB(K$)
變動 2022/12
RMB(K$)
2021/12
RMB(K$)
經營邊際利潤率(%)32.300%--36.062%70.493%
利息盈利率(x)21.769--32.197149.113
資產回報率(%)7.095%--7.877%13.315%
股東資金回報率(%)9.959%--10.663%16.769%

 

Copyright © 2025 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.